A Bill's Roadmap

The six stops, in order

Nebraska's Legislature is a unicameral — one chamber, 49 senators, no House and no Senate to pass a bill twice. That makes the roadmap shorter than most states', but it is not shorter than you'd think, and most bills never finish it.

The "reached / never reached" marks above are generic — they describe the roadmap itself, not any one bill. The worked example below shows exactly where a real bill stopped and why.

The worked example: LB474, the 2021 Medicinal Cannabis Act

Introduced by Sen. Anna Wishart on January 15, 2021. This is exactly how far it got, and no further.

LB474's final status, per the Legislature's own search results for bills introduced January 15, 2021: indefinitely postponed. (results page) The exact procedural step that formally closed it out, between May 12, 2021 and the end of the 107th Legislature, is not shown on the pages we have reviewed — flagged, not guessed at, on the full case-study page.

Read this carefully before you repeat it

A "no" vote on cloture is not a vote against medical cannabis. It is a vote to keep debating. Some of the 18 senators who voted no may have opposed the bill outright; others may have wanted more amendment time, objected to procedure, or had concerns about federal law. The roll call only shows what they voted, not why.

What the roll call does show: 31 senators — a clear majority — voted to end debate and let the bill move. It did not move, because ending debate on General File needs two-thirds, not a majority. That is not a flaw in the reporting. It is how the rule is written, and it is the whole reason this page exists.

What was actually at stake

Set that against the drug class a practitioner's recommendation is often meant to replace or reduce. Provisional CDC data reported roughly 54,700 opioid-involved overdose deaths in 2024 alone, down from about 83,100 in 2023 — both single years, not a 2021–2025 span. Nine, lifetime, in the broader cannabis count above, versus tens of thousands a year for opioids. That gap is the practical argument for the practitioner-protection bill this page is about — not a claim that cannabis has no risk at all.

Not yet confirmed word-for-word against the primary documents. `cdc.gov` is blocked from direct fetch in this session, the same way nebraskalegislature.gov was earlier — every figure above comes from a search-engine summary, not a direct read of the CDC's own pages. A separate fact-check (Science Feedback, 2024-10-30) found the flatter claim — "zero deaths from cannabis, ever" — overstated: cannabis still contributes to deaths indirectly, through impaired driving and falls, and in combination with other drugs. The 0.004% figure above is the narrower, checkable claim: cannabis by itself was virtually never the thing that killed someone in the CDC's own count. Homework owed: read cdc.gov/mmwr/volumes/75/wr/mm7534a2.htm and cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm directly and quote them exactly, rather than a summary of either.

The road didn't end at "indefinitely postponed"

LB474 is a dead bill number from 2021. The idea behind it was not dead — it kept moving through other doors, and the thread runs straight to a question we asked a sitting senator ourselves.

That seventh stop isn't on the Legislature's official roadmap. It's the one every reader of this page has access to too. When a bill stalls, the official process is done — but asking the person who sponsored it is not. We did it in writing, on the record, with the request and the date both published. Anyone can.

Who took pharmaceutical-industry money, and when

We checked all 18 of LB474's cloture "no" votes against Nebraska's own campaign finance filings — the Nebraska Accountability and Disclosure Commission's (NADC) contribution extracts, 2021–2026 — for direct corporate contributions from pharmaceutical companies and pharmacy-industry trade groups. Ten of the 18 took money from this industry. Eight took none that we found.

What this is not: no opioid manufacturer by name — Purdue, Mallinckrodt, Endo, Teva, Insys — turned up for anyone on the list. Most of this money also arrived after the May 12, 2021 cloture vote, in later campaign cycles — only a handful of contributions, mostly Arch's and Hilgers', predate it. This is not evidence that anyone was paid for that specific vote. It is evidence of an ongoing financial relationship between the pharmaceutical industry and several of the senators who kept LB474 from advancing, concentrated most heavily in the one who is now the state's chief law-enforcement officer and has fought the voter-approved version of this same law in court.

How to check this yourself: every figure above comes from NADC's own contribution extracts, filtered for company and trade-association names (Eli Lilly, Pfizer, Merck, Novartis, Astellas, CVS Health/Caremark, Walgreens, PhRMA, Pharmaceutical Care Management Association, Nebraska Pharmacists Association) and cross-checked against each senator's own candidate committee name. The search also covered — and found nothing for — generic "pharma"/"drug manufacturer" terms and five named opioid manufacturers. It did not cover every possible subsidiary or holding-company name, and "Business (For-Profit and Non-Profit entities)" contributions are not the same thing as a dedicated PAC — they are direct corporate gifts, which Nebraska allows. Look it up yourself at nadc.nebraska.gov.

Go deeper